Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesPhase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: CCTGcctg and SWOG study N0426
Journal of Clinical Oncology, 10/26/09
Adjei AA et al. – The purpose of this study was to evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. The study did not meet it's primary end point. However, the median PFS time of 4 months is promising. Pharmacogenetic studies in larger cohorts are needed to definitively identify polymorphisms that predict for survival and toxicity of pemetrexed.
Methods- Patients with previously treated NSCLC received pemetrexed (500 mg/m2 intravenous) combined with bevacizumab (15 mg/kg intravenous) every 3 weeks
- Primary end point, evaluated using one-stage Fleming design for detecting true success rate of at least 70%, was the proportion of patients who were progression free and on treatment at 3 months
- Polymorphisms in genes responsible for pemetrexed transport (reduced folate carrier [SLC19A1]) and metabolism (folylpolyglutamate synthase [FPGS] and gamma-glutamyl hydrolase [GGH]) evaluated in germline DNA (blood) correlated with treatment outcome
- 48 evaluable patients (14 females and 34 males) received a median of 4 cycles (range, one to 20 cycles)
- Most common grade 3 or 4 nonhematologic adverse events (AEs) were fatigue (13%), dyspnea (10%), and thrombosis (10%)
- Grade 3 or 4 hematologic AEs were neutropenia (19%) and lymphopenia (13%)
- 24 of the first 42 patients met success criteria
- Median overall survival (OS) and progression-free survival (PFS) times 8.6 and 4.0 months, respectively
- Exon 6 (2522)CT polymorphism in SLC19A1 correlated with 3-month progression-free status and with PFS
- IVS1(1307)CT polymorphism in GGH correlated with OS
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
Emergency Medicine Journal, 10/27/09
A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency Department
Archives of Pediatrics and Adolescent Medicine, 11/23/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
The Oncologist, 10/28/09
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Sponsor
Article Search
Sponsor